The Cholesterol You Were Born With: Why Lp(a) Changes Everything in 2026

Clinical Takeaway

Domain	Key Finding	Evidence Level
Causality	Mendelian randomization confirms Lp(a) is a causal driver of MI, stroke, PAD and aortic stenosis — not a passive marker.	Strong / genetic
Prevalence	~1 in 5 adults (≈1.4 billion people) carry Lp(a) above the risk threshold. Levels are ~80–90% genetically fixed and unmoved by diet, exercise, or statins.	Strong
The catch	Benefit tracks absolute mg/dL lowered, not percent. ~100 mg/dL of reduction may be needed to match a 1 mmol/L LDL drop.	MR estimate
Drugs (Phase 2)	siRNA/ASO agents cut Lp(a) 80–100%. Oral muvalaplin ~85%. None FDA-approved yet.	Phase 2 RCT
The verdict	Lp(a)HORIZON (pelacarsen, 8,323 pts) — the first-ever Lp(a) outcomes trial — reads out mid-2026.	Phase 3, pending
Gene editing	One-time in vivo CRISPR (CTX320) achieved ~90% Lp(a) reduction in primates; first human data due 1H 2026.	Phase 1, early
Do now	Measure Lp(a) once in every adult. If high: drive LDL/apoB, BP, and lifestyle to the floor and screen first-degree relatives.	Guideline-aligned

The Cholesterol You Were Born With